Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression

被引:78
作者
Chen, LH
Lu, WG
Agrawal, SH
Zhou, WQ
Zhang, RW
Chen, JD
机构
[1] Louisiana State Univ, Med Ctr, Stanley S Scott Canc Ctr, Dept Microbiol, New Orleans, LA 70112 USA
[2] Hybridon Inc, Cambridge, MA USA
[3] Univ Alabama, Div Clin Pharmacol, Birmingham, AL 35294 USA
关键词
D O I
10.1007/BF03402136
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: The MDM2 oncogene functions as a negative feedback regulator of the p53 tumor suppressor. Abnormal expression of MDM2 in tumors may attenuate the p53-mediated growth arrest and apoptosis response, resulting in increased cell proliferation and resistance to chemotherapy. Materials and Methods: We have developed phosphorothioate antisense oligodeoxynucleotides optimized for inhibition of MDM2 expression and investigated the role of MDM2 in a large panel of tumor cell lines. Results: Inhibition of MDM2 expression in 15 tumor types containing wild-type p53 results in a significant induction of nuclear p53 accumulation. The increase in p53 level is due to prolonged half-life and is associated with an increase in p53 transcriptional activity, growth inhibition, or apoptosis. Inhibition of MDM2 expression is also sufficient to induce nuclear p53 accumulation in several cell lines with cytoplasmic p53. Conclusions: The MDM2 negative feedback loop is important for maintenance of p53 at a low level by promoting p53 degradation. Nuclear export and degradation by MDM2 may contribute to the p53 nuclear exclusion phenotype. Inhibition of MDM2 expression can effectively activate p53 in most tumor types, including those without MDM2 overexpression, and may have broad anti-tumor potential.
引用
收藏
页码:21 / 34
页数:14
相关论文
共 37 条
  • [1] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [2] Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
    Bottger, A
    Bottger, V
    Sparks, A
    Liu, WL
    Howard, SF
    Lane, DP
    [J]. CURRENT BIOLOGY, 1997, 7 (11) : 860 - 869
  • [3] Chang YC, 1998, CELL GROWTH DIFFER, V9, P79
  • [4] MAPPING OF THE P53 AND MDM-2 INTERACTION DOMAINS
    CHEN, JD
    MARECHAL, V
    LEVINE, AJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (07) : 4107 - 4114
  • [5] Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage
    Chen, LH
    Agrawal, S
    Zhou, WQ
    Zhang, RW
    Chen, JD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (01) : 195 - 200
  • [6] CLARKE AR, 1994, ONCOGENE, V9, P1767
  • [7] CORDONCARDO C, 1994, CANCER RES, V54, P794
  • [8] TUMORIGENIC POTENTIAL ASSOCIATED WITH ENHANCED EXPRESSION OF A GENE THAT IS AMPLIFIED IN A MOUSE-TUMOR CELL-LINE
    FAKHARZADEH, SS
    TRUSKO, SP
    GEORGE, DL
    [J]. EMBO JOURNAL, 1991, 10 (06) : 1565 - 1569
  • [9] THE MDM-2 ONCOGENE CAN OVERCOME WILD-TYPE P53 SUPPRESSION OF TRANSFORMED-CELL GROWTH
    FINLAY, CA
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) : 301 - 306
  • [10] Goldman SC, 1996, AM J PATHOL, V148, P1381